153 related articles for article (PubMed ID: 12967055)
1. Patients with Alzheimer's disease living at home in France: costs and consequences of the disease.
Rigaud AS; Fagnani F; Bayle C; Latour F; Traykov L; Forette F
J Geriatr Psychiatry Neurol; 2003 Sep; 16(3):140-5. PubMed ID: 12967055
[TBL] [Abstract][Full Text] [Related]
2. Identifying factors of activities of daily living important for cost and caregiver outcomes in Alzheimer's disease.
Reed C; Belger M; Vellas B; Andrews JS; Argimon JM; Bruno G; Dodel R; Jones RW; Wimo A; Haro JM
Int Psychogeriatr; 2016 Feb; 28(2):247-59. PubMed ID: 26307191
[TBL] [Abstract][Full Text] [Related]
3. Dependence Levels as Interim Clinical Milestones Along the Continuum of Alzheimer's Disease: 18-Month Results from the GERAS Observational Study.
Kahle-Wrobleski K; Andrews JS; Belger M; Ye W; Gauthier S; Rentz DM; Galasko D
J Prev Alzheimers Dis; 2017; 4(2):72-80. PubMed ID: 29186278
[TBL] [Abstract][Full Text] [Related]
4. Cost and care of patients with Alzheimer's disease: clinical predictors in German health care settings.
Reese JP; Hessmann P; Seeberg G; Henkel D; Hirzmann P; Rieke J; Baum E; Dannhoff F; Müller MJ; Jessen F; Geldsetzer MB; Dodel R
J Alzheimers Dis; 2011; 27(4):723-36. PubMed ID: 21876256
[TBL] [Abstract][Full Text] [Related]
5. Donepezil for the treatment of mild to moderate Alzheimer's disease in France: the economic implications.
Fagnani F; Lafuma A; Pechevis M; Rigaud AS; Traykov L; Seux ML; Forette F
Dement Geriatr Cogn Disord; 2004; 17(1-2):5-13. PubMed ID: 14560059
[TBL] [Abstract][Full Text] [Related]
6. The GERAS Study: a prospective observational study of costs and resource use in community dwellers with Alzheimer's disease in three European countries--study design and baseline findings.
Wimo A; Reed CC; Dodel R; Belger M; Jones RW; Happich M; Argimon JM; Bruno G; Novick D; Vellas B; Haro JM
J Alzheimers Dis; 2013; 36(2):385-99. PubMed ID: 23629588
[TBL] [Abstract][Full Text] [Related]
7. Determinants of costs of care for patients with Alzheimer's disease.
Jönsson L; Eriksdotter Jönhagen M; Kilander L; Soininen H; Hallikainen M; Waldemar G; Nygaard H; Andreasen N; Winblad B; Wimo A
Int J Geriatr Psychiatry; 2006 May; 21(5):449-59. PubMed ID: 16676288
[TBL] [Abstract][Full Text] [Related]
8. Relation between severity of Alzheimer's disease and costs of caring.
Hux MJ; O'Brien BJ; Iskedjian M; Goeree R; Gagnon M; Gauthier S
CMAJ; 1998 Sep; 159(5):457-65. PubMed ID: 9757169
[TBL] [Abstract][Full Text] [Related]
9. The relation between disease severity and cost of caring for patients with Alzheimer disease in Canada.
Herrmann N; Tam DY; Balshaw R; Sambrook R; Lesnikova N; Lanctôt KL;
Can J Psychiatry; 2010 Dec; 55(12):768-75. PubMed ID: 21172097
[TBL] [Abstract][Full Text] [Related]
10. Resource Use and Cost of Alzheimer's Disease in France: 18-Month Results from the GERAS Observational Study.
Rapp T; Andrieu S; Chartier F; Deberdt W; Reed C; Belger M; Vellas B
Value Health; 2018 Mar; 21(3):295-303. PubMed ID: 29566836
[TBL] [Abstract][Full Text] [Related]
11. Determinants of societal costs in Alzheimer's disease: GERAS study baseline results.
Dodel R; Belger M; Reed C; Wimo A; Jones RW; Happich M; Argimon JM; Bruno G; Vellas B; Haro JM
Alzheimers Dement; 2015 Aug; 11(8):933-45. PubMed ID: 25846298
[TBL] [Abstract][Full Text] [Related]
12. An economic perspective on Alzheimer's disease.
Trabucchi M
J Geriatr Psychiatry Neurol; 1999; 12(1):29-38. PubMed ID: 10447152
[TBL] [Abstract][Full Text] [Related]
13. Resource utilisation, costs and clinical outcomes in non-institutionalised patients with Alzheimer's disease: 18-month UK results from the GERAS observational study.
Lenox-Smith A; Reed C; Lebrec J; Belger M; Jones RW
BMC Geriatr; 2016 Nov; 16(1):195. PubMed ID: 27887645
[TBL] [Abstract][Full Text] [Related]
14. The Potential Impact of Alzheimer's Disease Early Treatment on Societal Costs of Care in Czechia: A Simulation Approach.
Broulikova HM; Sladek V; Arltova M; Cerny J
J Ment Health Policy Econ; 2018 Dec; 21(4):147-161. PubMed ID: 30676992
[TBL] [Abstract][Full Text] [Related]
15. Relative importance of patient disease indicators on informal care and caregiver burden in Alzheimer's disease.
Bergvall N; Brinck P; Eek D; Gustavsson A; Wimo A; Winblad B; Jönsson L
Int Psychogeriatr; 2011 Feb; 23(1):73-85. PubMed ID: 20619068
[TBL] [Abstract][Full Text] [Related]
16. [Predictors of long-term institutionalization in patients with Alzheimer's disease: role of caregiver burden].
Hirono N; Tsukamoto N; Inoue M; Moriwaki Y; Mori E
No To Shinkei; 2002 Sep; 54(9):812-8. PubMed ID: 12428367
[TBL] [Abstract][Full Text] [Related]
17. Costs and Resource Use Associated with Community-Dwelling Patients with Alzheimer's Disease in Japan: Baseline Results from the Prospective Observational GERAS-J Study.
Nakanishi M; Igarashi A; Ueda K; Brnabic AJM; Treuer T; Sato M; Kahle-Wrobleski K; Meguro K; Yamada M; Mimura M; Arai H
J Alzheimers Dis; 2020; 74(1):127-138. PubMed ID: 31985460
[TBL] [Abstract][Full Text] [Related]
18. Costs of care in a mild-to-moderate Alzheimer clinical trial sample: key resources and their determinants.
Gustavsson A; Cattelin F; Jönsson L
Alzheimers Dement; 2011 Jul; 7(4):466-73. PubMed ID: 21784355
[TBL] [Abstract][Full Text] [Related]
19. Prospective one-year cost-of-illness study in a cohort of patients with dementia of Alzheimer's disease type in Spain: the ECO study.
Coduras A; Rabasa I; Frank A; Bermejo-Pareja F; López-Pousa S; López-Arrieta JM; Del Llano J; León T; Rejas J
J Alzheimers Dis; 2010; 19(2):601-15. PubMed ID: 20110605
[TBL] [Abstract][Full Text] [Related]
20. Exploring the relationship between Alzheimer's disease severity and longitudinal costs.
Rapp T; Andrieu S; Molinier L; Grand A; Cantet C; Mullins CD; Vellas B
Value Health; 2012 May; 15(3):412-9. PubMed ID: 22583450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
